the aid library

LIST OPTIONS

Filter

16657

Environmental Determinants of Cardiovascular Disease

Bhatnagar, A. Circulation Research (2018) CC

Many features of the environment have been found to exert an important influence on cardiovascular disease (CVD) risk, progression, and severity. Changes in the environment due to migration to different geographic locations, modifications in lifestyle choices, and shifts in social policies and cultu... more

Download (190)

View PDF (219)

Adolescent Girls in Disaster & Conflict: Interventions for Improving Access to Sexual and Reproductive Health Services

S. Guthridge-Gould UNFPA (United Nations Population Fund) (2016) C2

Download (768)

View PDF (1574)

Guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstratio

World Health Organization (2012)

Download (1386)

View PDF (1575)

Basic Epidemiology

Bonita, R.; R.Beaglehole, and T. Kjellström World Health Organization WHO (2006) C_WHO

2nd edition

Download (200)

View PDF (218)

TB Advocacy Guide - For People who use Drugs

hit.org.uk; INPUD (2019) C2

Accessed: 19.10.2019

Download (352)

View PDF (461)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (2281)

View PDF (2569)

WHO-WPR Emergency Response Manual

World Health Organization, Western Pacific Office (2003)

Guidelines for WHO Representatives and Country Offices in the Western Pacific Region

Download (481)

View PDF (661)

Toolkit on disability for AFRICA: INFORMATION AND COMMUNICATION TECHNOLOGY (ICT) AND DISABILITY

United Nations Division for Social Policy Development (DSPD) & United Nations Department of Economic and Social Affairs (DESA) (2016) C1

Module 12

Download (261)

View PDF (330)

Global clinical data platform for severe acute hepatitis of unknown aetiology in children case report form (CRF)

World Health Organization WHO (2022) C_WHO

Multiple countries are reporting severe acute cases of hepatitis of unknown aetiology in children, in several regions of the world. WHO has developed this clinical case report form (CRF) to support and facilitate reporting of anonymized, patient-level data of acute hepatitis of unknown aetiology.

External Link

Communicable disease surveillance and response systems

World Health Organization (2006)

Guide to monitoring and evaluating

Download (541)

View PDF (1794)

Ankommen - Gehiştin - Welcome - خوش آمدید - ترحيب - Добро пожаловать! Information for female refugees in Bremen

Bremische Zentralstelle für die Verwirklichung der Gleichberechtigung der Frau (ZGF) (2018) C1

Nice multilingual information brochure for refugee women arriving in Germany/Bremen. Includes Information on: - Learn German - Education & Employment - Healthcare & Pregnancy - Protection against Violence - Asylum for Women - Conversation and Contacts in the City All chapters are translated i... more

Download (432)

View PDF (694)

Education Capacity Self-Assessment: Transforming the Education Humanitarian Response of the Rohingya Refugee Crisis (Cox’s Bazar, Bangladesh, March 2018)

UN Children's Fund, BRAC, Education Cluster, Norwegian Capacity (2018) CC

Download (2366)

View PDF (2985)

Combined course on growth assessment and IYCF counselling. Participant's Manual

World Health Organization (2012) C_WHO

Download (5699)

View PDF (1601)

Pharmaceutical management and prescribing pattern of antimalarial drugs in the public health facilities in Dar-es-Salaam, Tanzania

Richard Sebastian Silumbe (2011) C1

Master of Science in Pharmaceutical Management Dissertation

External Link

Ebola emergency preparedness in EU Member States: Conclusions from peer-review visits to Belgium, Portugal and Romania

ECDC (European Centre for Disease Prevention and Control) (2015) CC2

This report presents the main characteristics of Ebola emergency preparedness in three EU Member States. Findings are organised in five sections: preparedness planning, organisational structures, recourses and capacities, intersectoral and cross-border collaboration, and country-specific findings